Testing disagreements hamper Ebola vax search; Admedus begins PhII trial of herpes jab;

> As the Ebola outbreak wanes, disagreements over the most effective testing methods may mean potential vaccines aren't thoroughly vetted. Story

> Admedus Limited will begin a Phase II study of its herpes vaccine this month. More

> Research Triangle Park, NC-based Argos Therapeutics ($ARGS) struck a deal with China-based Lummy Hong Kong to develop cancer immunotherapies in China. Report

> Daiichi Sankyo and Terumo announced their application for manufacturing and sales approval of an intradermal seasonal influenza vaccine in Japan. Release

> GeoVax will seek a dual pathway for advancing its HIV vaccine into human trials. Release

> Scientists believe a new HIV treatment pioneered using an antibody to attack the virus could lead to a vaccine to prevent the infection. Story

And Finally... Los Angeles artist Mary Beth Heffernan delivered a way for Ebola patients to see the faces of those helping. Story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.